35 results about "Cardiac failure therapy" patented technology

Methods and apparatus for assessing the condition of and treating patients for heart failure by the delivery of continuous positive airway pressure are disclosed. Airflow of the patient is measured to determine occurrences of central apneas. A heart failure index is calculated from a count of the number of central apneas that have occurred. The present heart failure index can be compared with a previously calculated heart failure index to determine how the patient's heart failure disease has changed and how it should be treated.

The present invention provides methods for screening drugs inhibiting the expression of OSF-2 gene or the production or function of the protein encoded thereby and therapeutic agents for heart failure having such effects. Useful methods for diagnosing heart failure can be provided by monitoring the expression or variation of said gene or the production of the protein encoded thereby. The present invention also provides transgenic animals with forced expression of OSF-2 gene and methods for studying changes in gene expression or protein production or the functions of various genes or proteins with the progress of the pathology of heart failure using them and novel therapeutic agents for heart failure.

A method and apparatus for treating heart failure is configured to be placed about at least a portion of a patient's heart to apply a mild compressive force on the heart over a range of elastic deformation of the apparatus. The apparatus can be shifted to second range of deformation. In some embodiments, the apparatus is shifted to the second range of deformation by application of a stimulus or alteration of environmental conditions beyond a threshold level.

The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B-type natriuretic protein; (l) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; or (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has a Arg389Arg polymorphism and/or a Gly389Gly polymorphism in the beta 1 adrenergic receptor gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.

A water-soluble extract of red sage root containing danshinolic acid B, danshensu and proshikonic acid, its preparing process, and its application in preparing the angiotonin converzyme depressant medicines for treating hypertension, and hypertension accompanied by heart failure or diabetes or nephrosis are disclosed.

There is currently no completely effective treatment for heart failure. Considering the need for, and current void in the medical field for, a treatment for heart failure, the invention is drawn to treating heart failure. In particular aspects, the invention is drawn to the discovery that certain polyunsaturated fatty acids (PUFAs) and doses thereof are useful for treating heart failure. In other particular aspects, the invention is drawn to the discovery that certain PUFAs and doses thereof are useful for preserving mitochondrial function in a heart failure subject.

The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. The present invention also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein.

The present invention relates to novel treatments of mammalian and human heart failure directed at improving cardiac creatine kinase metabolism, the prime energy reserve of cardiac muscle. The invention also relates to novel treatments using gene transfer vectors to increase myocardial creatine kinase protein expression and/or creatine kinase activity, as well as flux through the creatine kinase reaction and to thereby improve cardiac contractile function and ameliorate remodeling in heart failure. The invention further relates to methods for screening and identifying compounds that increase creatine kinase expression and/or creatine kinase activity as potential pharmaceutical compositions for heart failure therapy.

Bioengineering the regenerative heart or other body organ in need of greater muscle mass or improved blood perfusion provides a novel treatment for organ weakness or failure. In the case of cardiac failure treatment, on May 14, 2002, a 55-year-old man suffering ischemic myocardial infarction received 25 injections carrying 465 million cGMP-produced pure myoblasts into his myocardium after coronary artery bypass grafting. Three myogenesis mechanisms were elucidated with 17 human/porcine xenografts using cyclosporine as immunosuppressant. Some myoblasts developed to become cardiomyocytes. Others transferred their nuclei into host cardiomyocytes through natural cell fusion. As yet others formed skeletal myofibers with satellite cells. De novo production of contractile filaments augmented heart contractility. Human myoblasts transduced with VEGF165 gene produced six times more capillaries in porcine myocardium than placebo. Xenograft rejection was not observed for up to 20 weeks despite cyclosporine discontinuation at 6 weeks.

The present invention relates to a method for guiding heart failure treatment in a subject suffering from heart failure. The method is based on the determination of the amount of a BNP-type peptide and a cardiac troponin in a sample from said subject. Further envisaged by the present invention are kits and devices adapted to carry out the present invention. The present invention also relates to a system for guiding heart failure treatment in a subject suffering from heart failure as disclosed herein and to reagents and kits used in performing the methods disclosed herein.

The present invention relates to treating and/or preventing heart failure or one or more individual heart failure phenotypes in mammals using placental growth factor 2 (PlGF-2).

The invention provides a pharmaceutical composition for treating heart failure. The pharmaceutical composition is prepared from 12-18 parts by weight of radix bupleuri, 16-24 parts by weight of oyster, 16-24 parts by weight of radix angelicae sinensis, 40-60 parts by weight of spina date seed, 24-36 parts by weight of cortex acanthopanacis giraldii, 16-24 parts by weight of raw sun ginseng, 8-12 parts by weight of cassia bark and 12-18 parts by weight of radix polygonati officinalis. The invention also provides a preparation method and use of the pharmaceutical composition. The pharmaceuticalcomposition has reasonable compatibility and good therapeutic effects on various heart failures, has good safety and provides a novel clinical drug.

The invention discloses a medicine composition for treating congestive heart failure and application thereof. The medicine composition is prepared from supernate obtained through treating the following traditional Chinese medicinal materials by a water extraction and alcohol sedimentation method: 9 to 15 parts of lineate supplejack leaves, 15 to 22 parts of black beans, 4 to 8 parts of bitter citrus immature flowers, 27 to 33 parts of millettia specisoa champ roots, 4 to 8 parts of spinach fruits, 12 to 18 parts of radices hemerocallis, 9 to 15 parts of barbate cyclea roots or stems, 12 to 18 parts of dry lotus leaves and 15 to 22 parts of wideleaf osbeckia roots. When the medicine composition is used as the medicine for treating the congestive heart failure, the medicine effect is comprehensive; the illness state of patients with congestive heart failure can be fast relieved; the heart failure death rate is reduced.

The present invention relates to S100 protein and nuclei acids encoding S100 protein for enhancing the cardiac power as well as vectors and pharmaceuticals comprising the same and uses thereof.

The present invention provides a method of evaluating pathological conditions of heart failure based on a new mechanism of action of heart failure, a method of evaluating a candidate compound for a heart failure treatment drug using the mechanism of action, and a pharmaceutical composition for treating or preventing heart failure using the mechanism of action. That is, the present invention provides a method of evaluating pathological conditions of heart failure including measuring an amount of succinyl-CoA in cardiomyocytes collected from a test animal, a respiratory capacity of mitochondrial complex II in peripheral blood mononuclear cells collected from the test animal or an amount of reactive oxygen species released from peripheral blood mononuclear cells collected from the test animal; and evaluating the onset of heart failure of the test animal or the severity of heart failure based on the obtained measurement values.